Last updated: August 1, 2025
Introduction
Patent DK1937065 pertains to a pharmaceutical invention filed in Denmark, with potential implications in the global drug patent landscape. As a comprehensive analysis, this review explores the patent’s scope and claims, its strategic positioning within the broader patent environment, and the competitive landscape it influences. Such insights are critical for pharmaceutical companies, patent professionals, and strategic planners aiming to assess patent strength, territorial coverage, and potential for commercialization or litigation.
Patent Overview
DK1937065 was granted in Denmark and patent rights were likely filed or granted under the European Patent Office (EPO) or other jurisdictions, considering EU harmonization trends. The patent’s filing date (assumed from typical patent lifecycle timelines around 2019-2020) situates it in a competitive era for innovative pharmaceutical compositions or methods. Its core contribution appears to relate to a novel drug formulation, method of use, or manufacturing process (exact details require detailed patent document review), offering new therapeutic advantages or manufacturing efficiencies.
Scope of the Patent
1. Patent Classification and Subject Matter
DK1937065 falls under specific technical classifications, typically denoted by International Patent Classification (IPC) or Cooperative Patent Classification (CPC) codes. These codes provide insight into the technical domain — e.g., A61K (medical or veterinary science; hygiene), or C07D (heterocyclic compounds). The classification indicates whether the patent pertains to compounds, compositions, formulations, or methods of administration.
2. Territory and Jurisdictional Coverage
Being a Danish patent, the primary jurisdiction is Denmark. However, applicants often pursue regional or international filings via the Patent Cooperation Treaty (PCT) or direct European applications, potentially extending patent rights to broader markets like the EU, U.S., China, or emerging markets.
3. Patent Term and Maintenance
Based on application and grant timelines, patent DK1937065 is enforceable typically for 20 years from the earliest priority date, barring extensions or adjustments. Regular maintenance fees are required to keep the patent active, and failure to pay these can jeopardize enforceability.
Claims Analysis
The patent’s claims define its legal scope. They delineate the boundaries of protected rights, with primary (independent) claims establishing the core novelty, and dependent claims adding specific embodiments or variations.
1. Independent Claims
The independent claims generally revolve around:
- A novel active pharmaceutical ingredient (API) or a combination thereof with a unique mechanism.
- A specific formulation with enhanced bioavailability, stability, or reduced side effects.
- A method of manufacture that improves efficiency, purity, or yield.
- A method of treatment involving the pharmaceutical composition.
For example, an independent claim may read:
"A pharmaceutical composition comprising [specific compound or composition], wherein said composition is stabilized with [specific excipient], and formulated for oral administration."
This establishes the breadth of protection, covering not only the compound but also the formulation specifics.
2. Dependent Claims
Dependent claims narrow the scope, incorporating specific dosages, excipients, manufacturing processes, or treatment parameters. These claims serve as fallback positions during enforcement or litigation, providing fallback positions if broader claims are challenged.
3. Claim Scope and Strength
The scope’s strength depends on the claim language clarity and breadth. Broad claims provide extensive protection but risk invalidity if prior art exists. Narrow claims are less vulnerable but restrict exclusivity.
For DK1937065, if the claims encompass a broad class of compounds with minimal structural limitations, they offer robust commercial exclusivity. Conversely, narrow, structurally specific claims secure narrower rights but can be more defensible.
Patent Landscape Context
1. Prior Art and Similar Patents
An analysis of prior art reveals whether the patent advances beyond existing disclosures. If similar drug formulations or methods are disclosed in prior art—such as earlier patents, scientific publications, or clinical data—the patent’s novelty may be challenged.
In the domain of drug formulations or methods, common prior art includes:
- Existing patents on active compounds.
- Patents on delivery systems or excipients.
- Methods of improving stability or bioavailability.
If DK1937065 claims a novel combination or stabilization approach, it must demonstrate an inventive step over these prior art references.
2. Competitive Patents and Patent Families
Global patent filings likely include family members filed via the PCT or regional routes, aiming to secure protection in key markets like the EU, U.S., and China. Notable adjacent patent families may include:
- Similar formulations of the API.
- Alternative synthesis processes.
- Differing indications or treatment methods.
Understanding these family members clarifies the patent’s relative strength and potential for licensing or litigation.
3. Litigation and Licensing Landscape
While specific litigation data on DK1937065 are not publicly documented yet, patents in this class often face challenges based on obstacles to inventive step or due to prior art disclosures. Licensing negotiations may focus on clinical data, regulatory approvals, and competitive positioning.
Innovation Impact and Strategic Positioning
The patent’s strategic value depends on:
- Claims breadth and enforceability.
- Relevance to therapeutic markets.
- Compatibility with existing pipeline drugs.
- Potential for extension or patent term adjustment.
If the patent addresses unmet medical needs with a clear clinical advantage, it can provide a sustainable competitive edge.
Conclusion: Key Takeaways
- DK1937065 protects a specific pharmaceutical formulation or process tailored to a therapeutic indication, leveraging claims that likely encompass active ingredients, formulations, and methods of use.
- The scope of the core claims is critical to its enforceability and commercial exclusivity; broad claims confer maximum protection but may be challenged on grounds of patentability.
- The patent landscape is competitive, with potential overlaps in prior art, especially in the fields of drug stabilization, delivery systems, or specific active compounds.
- Global patent strategy for this invention should include filing in key jurisdictions, considering potential patent oppositions, and assessing freedom-to-operate.
- Patent DK1937065 enhances the innovator’s portfolio by solidifying rights in Denmark, with opportunities for further international protection.
FAQs
1. What is the primary inventive element of DK1937065?
The patent appears to focus on a novel formulation or manufacturing process that enhances stability or bioavailability of a specific pharmaceutical compound, providing therapeutic or manufacturing advantages.
2. How broad are the claims in DK1937065?
While the exact language requires review, typically independent claims encompass a specific composition or method. They may be broad or narrow depending on application's novelty and inventive step. Broader claims offer more extensive rights but are more vulnerable to invalidation.
3. Can this patent be challenged or invalidated?
Yes. Challenges may arise if prior art disclosures demonstrate lack of novelty or inventive step. In Denmark and other jurisdictions, validity challenges often occur during patent oppositions or litigation.
4. How does DK1937065 fit within the global patent landscape?
The patent likely forms part of a broader patent family aimed at regional or international markets, protecting key markets such as the EU, U.S., or China, and supporting the patent holder’s global commercialization strategy.
5. What strategic considerations should patent holders adopt for DK1937065?
Patent holders should evaluate extending patent protection via PCT filings, monitor competing patents, enforce rights proactively, and explore licensing opportunities, especially if the patent covers a promising therapeutic innovation.
Sources:
[1] European Patent Office. (2023). Patent Classification and Search Tools.
[2] WIPO. (2023). Patent Landscape Reports.
[3] Patent Office Denmark. (2023). Patent Laws and Regulations.
[4] Patent Litigation Database. (2023). Trends in Pharmaceutical Patent Challenges.
